JP2022533182A - タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 - Google Patents
タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 Download PDFInfo
- Publication number
- JP2022533182A JP2022533182A JP2021568650A JP2021568650A JP2022533182A JP 2022533182 A JP2022533182 A JP 2022533182A JP 2021568650 A JP2021568650 A JP 2021568650A JP 2021568650 A JP2021568650 A JP 2021568650A JP 2022533182 A JP2022533182 A JP 2022533182A
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- ripk3
- pyrimidine
- kinase
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 title claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 18
- 238000011282 treatment Methods 0.000 title description 12
- 239000003909 protein kinase inhibitor Substances 0.000 title description 7
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 41
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 41
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 26
- 108060006633 protein kinase Proteins 0.000 claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 18
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 16
- 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 claims abstract description 6
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims abstract 9
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims abstract 9
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims description 60
- 241000712431 Influenza A virus Species 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 19
- -1 carrier Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000006414 CCl Chemical group ClC* 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000010799 Receptor Interactions Effects 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229910014033 C-OH Inorganic materials 0.000 claims description 3
- 229910014570 C—OH Inorganic materials 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 abstract description 63
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000003412 degenerative effect Effects 0.000 abstract description 5
- 230000009977 dual effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 141
- 239000007787 solid Substances 0.000 description 127
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- 235000019439 ethyl acetate Nutrition 0.000 description 65
- 239000011541 reaction mixture Substances 0.000 description 62
- 239000000243 solution Substances 0.000 description 53
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 50
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 239000000741 silica gel Substances 0.000 description 30
- 229910002027 silica gel Inorganic materials 0.000 description 30
- 238000004440 column chromatography Methods 0.000 description 28
- 230000021597 necroptosis Effects 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- 229910052786 argon Inorganic materials 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 18
- 230000030833 cell death Effects 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 102000003390 tumor necrosis factor Human genes 0.000 description 15
- 230000006907 apoptotic process Effects 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 10
- 229910000175 cerite Inorganic materials 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 208000004852 Lung Injury Diseases 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 231100000515 lung injury Toxicity 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- HCYCPZFHVYEOER-UHFFFAOYSA-N 6-bromo-N-(3-methylsulfonylphenyl)quinazolin-2-amine Chemical compound BrC=1C=C2C=NC(=NC2=CC=1)NC1=CC(=CC=C1)S(=O)(=O)C HCYCPZFHVYEOER-UHFFFAOYSA-N 0.000 description 7
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 7
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 7
- 206010069363 Traumatic lung injury Diseases 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000001338 necrotic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- DMYSBMDUVXRMJU-UHFFFAOYSA-N 6-(2-chloro-4-methylphenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)C)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C DMYSBMDUVXRMJU-UHFFFAOYSA-N 0.000 description 6
- KBFYJXMMAXTGQP-UHFFFAOYSA-N 6-chloro-4-(methylamino)pyridine-3-carbaldehyde Chemical compound CNC1=CC(Cl)=NC=C1C=O KBFYJXMMAXTGQP-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- YVBIXOXCIOUBMY-UHFFFAOYSA-N [6-chloro-4-(methylamino)pyridin-3-yl]methanol Chemical compound CNC1=CC(Cl)=NC=C1CO YVBIXOXCIOUBMY-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000007630 basic procedure Methods 0.000 description 6
- DEAFVBVKIMXSND-UHFFFAOYSA-N ethyl 6-chloro-4-(methylamino)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C=C1NC DEAFVBVKIMXSND-UHFFFAOYSA-N 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- WGUCZWYLSKPURM-UHFFFAOYSA-N 4-(methylamino)-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CNC1=NC(SC)=NC=C1C=O WGUCZWYLSKPURM-UHFFFAOYSA-N 0.000 description 5
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000006721 cell death pathway Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 4
- FGONQMFYFJRAIG-UHFFFAOYSA-N 4-amino-2-methylsulfanylpyrimidine-5-carbaldehyde Chemical compound CSC1=NC=C(C=O)C(N)=N1 FGONQMFYFJRAIG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- IKWPXQBMCNBGEG-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C IKWPXQBMCNBGEG-UHFFFAOYSA-N 0.000 description 4
- SVBLFAQKAOTDFU-UHFFFAOYSA-N 6-(2-chloro-4-methylphenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)C)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C SVBLFAQKAOTDFU-UHFFFAOYSA-N 0.000 description 4
- NYQBZJFZEZEXFP-UHFFFAOYSA-N 6-bromo-2-chloroquinazoline Chemical compound C1=C(Br)C=CC2=NC(Cl)=NC=C21 NYQBZJFZEZEXFP-UHFFFAOYSA-N 0.000 description 4
- DHKLJXPNLNWRLZ-UHFFFAOYSA-N 6-bromo-N-[4-[2-(diethylamino)ethoxy]phenyl]quinazolin-2-amine Chemical compound BrC=1C=C2C=NC(=NC2=CC=1)NC1=CC=C(C=C1)OCCN(CC)CC DHKLJXPNLNWRLZ-UHFFFAOYSA-N 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- SNNHLSHDDGJVDM-UHFFFAOYSA-N ethyl 4-chloro-2-methylsulfanylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(SC)N=C1Cl SNNHLSHDDGJVDM-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- XLVOWGDFXAVSFE-UHFFFAOYSA-N (4-amino-2-methylsulfanylpyrimidin-5-yl)methanol Chemical compound CSC1=NC=C(CO)C(N)=N1 XLVOWGDFXAVSFE-UHFFFAOYSA-N 0.000 description 3
- CUAUTGRQMYJPFC-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-8-ethyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C=CC=CC=2)C(=O)N2CC)C2=N1 CUAUTGRQMYJPFC-UHFFFAOYSA-N 0.000 description 3
- AABYCBJQCOPZML-UHFFFAOYSA-N 3-(1,1-dioxo-1,4-thiazinan-4-yl)aniline Chemical compound NC1=CC=CC(N2CCS(=O)(=O)CC2)=C1 AABYCBJQCOPZML-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- LFJGGGIWERIGNX-UHFFFAOYSA-N 4-[2-(diethylamino)ethoxy]aniline Chemical compound CCN(CC)CCOC1=CC=C(N)C=C1 LFJGGGIWERIGNX-UHFFFAOYSA-N 0.000 description 3
- LATMRUSMLRSPOU-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)C LATMRUSMLRSPOU-UHFFFAOYSA-N 0.000 description 3
- AJICYMQAPFTFJW-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C AJICYMQAPFTFJW-UHFFFAOYSA-N 0.000 description 3
- ZOLPTXOZGBDIDY-UHFFFAOYSA-N 6-(2-chloro-4-fluorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)F)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C ZOLPTXOZGBDIDY-UHFFFAOYSA-N 0.000 description 3
- OMLZCXJVYHKTKX-UHFFFAOYSA-N 6-(2-chloro-4-methylphenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)C)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C OMLZCXJVYHKTKX-UHFFFAOYSA-N 0.000 description 3
- YMCJVINRUYZBOB-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-(3-piperazin-1-ylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)N2CCNCC2)N(C1=O)C YMCJVINRUYZBOB-UHFFFAOYSA-N 0.000 description 3
- XMJBSGYDACBKMY-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C XMJBSGYDACBKMY-UHFFFAOYSA-N 0.000 description 3
- WKJKSHGZNWFXCD-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound CSc1ncc2cc(-c3ccc(O)cc3)c(=O)n(C)c2n1 WKJKSHGZNWFXCD-UHFFFAOYSA-N 0.000 description 3
- OLIVQCGSZZJHAF-UHFFFAOYSA-N 6-(4-methoxyphenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound COc1ccc(cc1)-c1cc2cnc(SC)nc2n(C)c1=O OLIVQCGSZZJHAF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- 102000004091 Caspase-8 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- CIKTYIPDZNLIDJ-UHFFFAOYSA-N N-[4-[2-(diethylamino)ethoxy]phenyl]formamide Chemical compound C(C)N(CCOC1=CC=C(C=C1)NC=O)CC CIKTYIPDZNLIDJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 231100000516 lung damage Toxicity 0.000 description 3
- OONQSUFLXZFOLA-UHFFFAOYSA-N n-(3-methylsulfonylphenyl)formamide Chemical compound CS(=O)(=O)C1=CC=CC(NC=O)=C1 OONQSUFLXZFOLA-UHFFFAOYSA-N 0.000 description 3
- ZCDBTQNFAPKACC-UHFFFAOYSA-N n-(6-propan-2-ylsulfonylquinolin-4-yl)-1,3-benzothiazol-5-amine Chemical compound C1=C2SC=NC2=CC(NC2=CC=NC3=CC=C(C=C32)S(=O)(=O)C(C)C)=C1 ZCDBTQNFAPKACC-UHFFFAOYSA-N 0.000 description 3
- NOCSAAHHSOQRCI-UHFFFAOYSA-N n-pyridin-2-ylformamide Chemical compound O=CNC1=CC=CC=N1 NOCSAAHHSOQRCI-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- UKYCKUPXBPLXBA-UHFFFAOYSA-N (2-chloro-4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C(Cl)=C1 UKYCKUPXBPLXBA-UHFFFAOYSA-N 0.000 description 2
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VJARIBGMDPJLCL-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=C(CC#N)C(Cl)=C1 VJARIBGMDPJLCL-UHFFFAOYSA-N 0.000 description 2
- AOFHPWKDAJCJHE-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-8-(2-hydroxyethyl)-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)N(CCOC1=CC=C(C=C1)NC=1N=CC2=C(N=1)N(C(C(=C2)C1=CC=CC=C1)=O)CCO)CC AOFHPWKDAJCJHE-UHFFFAOYSA-N 0.000 description 2
- XGUIEYMNFRMLPV-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-8-methyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C=CC=CC=2)C(=O)N2C)C2=N1 XGUIEYMNFRMLPV-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- RJGHJWKQCJAJEP-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=CC(N)=C1 RJGHJWKQCJAJEP-UHFFFAOYSA-N 0.000 description 2
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 2
- WZJSEOATGOTFNY-UHFFFAOYSA-N 4-(3-nitrophenyl)-1,4-thiazinane 1,1-dioxide Chemical compound [O-][N+](=O)C1=CC=CC(N2CCS(=O)(=O)CC2)=C1 WZJSEOATGOTFNY-UHFFFAOYSA-N 0.000 description 2
- SBTAGVYSJMZSQE-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=C(C=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C SBTAGVYSJMZSQE-UHFFFAOYSA-N 0.000 description 2
- GUOZHNHJTXGTIQ-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=C(C=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C GUOZHNHJTXGTIQ-UHFFFAOYSA-N 0.000 description 2
- MBFQPUZSYLGVET-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=C(C=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C MBFQPUZSYLGVET-UHFFFAOYSA-N 0.000 description 2
- YBDMDASOVBUGSC-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-(2-methylpropyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)CC(C)C YBDMDASOVBUGSC-UHFFFAOYSA-N 0.000 description 2
- QXZQWTRSWYLAFO-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-[(3-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)CC1=CC(=CC=C1)S(=O)(=O)C QXZQWTRSWYLAFO-UHFFFAOYSA-N 0.000 description 2
- VNJSERLEIJDSJV-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-[(4-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)CC1=CC=C(C=C1)S(=O)(=O)C VNJSERLEIJDSJV-UHFFFAOYSA-N 0.000 description 2
- LRVMKRQQVSSYSR-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8-[(3-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CC1=CC(=CC=C1)S(=O)(=O)C LRVMKRQQVSSYSR-UHFFFAOYSA-N 0.000 description 2
- UHSFMLWTMAUOTK-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8-[(4-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CC1=CC=C(C=C1)S(=O)(=O)C UHSFMLWTMAUOTK-UHFFFAOYSA-N 0.000 description 2
- KPRCKNFYMXVRCB-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfanyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1NC2=NC(SC)=NC=C2C=C1C1=C(Cl)C=CC=C1Cl KPRCKNFYMXVRCB-UHFFFAOYSA-N 0.000 description 2
- WLWJJKVNIOIIEU-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfonyl-8-[(3-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CC1=CC(=CC=C1)S(=O)(=O)C WLWJJKVNIOIIEU-UHFFFAOYSA-N 0.000 description 2
- UDRCNOJXKFMKMD-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-methylsulfonyl-8-[(4-methylsulfonylphenyl)methyl]pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CC1=CC=C(C=C1)S(=O)(=O)C UDRCNOJXKFMKMD-UHFFFAOYSA-N 0.000 description 2
- RSRLLINYTJHRCA-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-(2-methoxyethyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CCOC RSRLLINYTJHRCA-UHFFFAOYSA-N 0.000 description 2
- YTTDACRYINJOTE-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-(2-methoxyethyl)-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CCOC YTTDACRYINJOTE-UHFFFAOYSA-N 0.000 description 2
- GHIRKOYLRMQNAF-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C GHIRKOYLRMQNAF-UHFFFAOYSA-N 0.000 description 2
- LCKCHOMHDSHDJF-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(SC)=NC=C2C=C1C1=C(Cl)C=CC=C1Cl LCKCHOMHDSHDJF-UHFFFAOYSA-N 0.000 description 2
- BADVXFUKYQHVBO-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(S(C)(=O)=O)=NC=C2C=C1C1=C(Cl)C=CC=C1Cl BADVXFUKYQHVBO-UHFFFAOYSA-N 0.000 description 2
- KIHKWCNGGYKWJU-UHFFFAOYSA-N 6-(2-chloro-4-fluorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)F)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C KIHKWCNGGYKWJU-UHFFFAOYSA-N 0.000 description 2
- DJKHWQKHUPEYFK-UHFFFAOYSA-N 6-(2-chloro-4-fluorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)F)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C DJKHWQKHUPEYFK-UHFFFAOYSA-N 0.000 description 2
- ALEALKZBRLEOJZ-UHFFFAOYSA-N 6-(2-chlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)C ALEALKZBRLEOJZ-UHFFFAOYSA-N 0.000 description 2
- GPAVSRFSJCTRBG-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(SC)=NC=C2C=C1C1=CC=CC=C1Cl GPAVSRFSJCTRBG-UHFFFAOYSA-N 0.000 description 2
- XFOWYVBQBQMUAH-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(S(C)(=O)=O)=NC=C2C=C1C1=CC=CC=C1Cl XFOWYVBQBQMUAH-UHFFFAOYSA-N 0.000 description 2
- BKKLKDBGZYFYHB-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)C BKKLKDBGZYFYHB-UHFFFAOYSA-N 0.000 description 2
- PWQZNGLXWFPWHS-UHFFFAOYSA-N 6-(4-chlorophenyl)-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)SC)NC1=O PWQZNGLXWFPWHS-UHFFFAOYSA-N 0.000 description 2
- IWKOGJYABSALSF-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-(2-methylpropyl)-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)CC(C)C IWKOGJYABSALSF-UHFFFAOYSA-N 0.000 description 2
- XDPFREWMZLZKEE-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-(2-methylpropyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CC(C)C XDPFREWMZLZKEE-UHFFFAOYSA-N 0.000 description 2
- PCHATNUAXGFSIQ-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-(2-methylpropyl)-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CC(C)C PCHATNUAXGFSIQ-UHFFFAOYSA-N 0.000 description 2
- TWLGRDCGDNJMOF-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C TWLGRDCGDNJMOF-UHFFFAOYSA-N 0.000 description 2
- YISXPUJRNVVHRT-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound OC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C YISXPUJRNVVHRT-UHFFFAOYSA-N 0.000 description 2
- GTFQUQGCWGESDG-UHFFFAOYSA-N 6-(4-methoxyphenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound COC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C GTFQUQGCWGESDG-UHFFFAOYSA-N 0.000 description 2
- UXONUTCSTCAEAZ-UHFFFAOYSA-N 6-(4-methoxyphenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound COC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C UXONUTCSTCAEAZ-UHFFFAOYSA-N 0.000 description 2
- LXFRLBOLLMEJTK-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)OCCN(CC)CC)N(C1=O)C LXFRLBOLLMEJTK-UHFFFAOYSA-N 0.000 description 2
- CDEYNSJIONMJNM-UHFFFAOYSA-N 6-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound [Si](C)(C)(C(C)(C)C)OC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C CDEYNSJIONMJNM-UHFFFAOYSA-N 0.000 description 2
- MWVLKXHKJCENJR-UHFFFAOYSA-N 8-(2-hydroxyethyl)-2-methylsulfanyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound OCCN1C(C(=CC2=C1N=C(N=C2)SC)C1=CC=CC=C1)=O MWVLKXHKJCENJR-UHFFFAOYSA-N 0.000 description 2
- YSMOECQOOXGKLY-UHFFFAOYSA-N 8-(2-hydroxyethyl)-2-methylsulfonyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound OCCN1C(C(=CC2=C1N=C(N=C2)S(=O)(=O)C)C1=CC=CC=C1)=O YSMOECQOOXGKLY-UHFFFAOYSA-N 0.000 description 2
- YYOFUULRDCRFOA-UHFFFAOYSA-N 8-methyl-2-methylsulfanyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(SC)=NC=C2C=C1C1=CC=CC=C1 YYOFUULRDCRFOA-UHFFFAOYSA-N 0.000 description 2
- AYYAGZHKFLLINM-UHFFFAOYSA-N 8-methyl-2-methylsulfonyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(C)C2=NC(S(C)(=O)=O)=NC=C2C=C1C1=CC=CC=C1 AYYAGZHKFLLINM-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229910010199 LiAl Inorganic materials 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000005475 Vascular calcification Diseases 0.000 description 2
- NXNGLEYSIAXGCL-UHFFFAOYSA-N [4-(methylamino)-2-methylsulfanylpyrimidin-5-yl]methanol Chemical compound CNC1=NC(SC)=NC=C1CO NXNGLEYSIAXGCL-UHFFFAOYSA-N 0.000 description 2
- RDCOMWQFSWWPJG-UHFFFAOYSA-N acetyl acetate;formic acid Chemical compound OC=O.CC(=O)OC(C)=O RDCOMWQFSWWPJG-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000005741 alkyl alkenyl group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- IUUDCMFVEMKOBT-UHFFFAOYSA-N n-(4-methylsulfonylphenyl)formamide Chemical compound CS(=O)(=O)C1=CC=C(NC=O)C=C1 IUUDCMFVEMKOBT-UHFFFAOYSA-N 0.000 description 2
- CBKFHSNATJJWQK-UHFFFAOYSA-N n-pyridin-3-ylformamide Chemical compound O=CNC1=CC=CN=C1 CBKFHSNATJJWQK-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 2
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- LHHZRIYUOZPKSG-UHFFFAOYSA-N 1-(3-nitrophenyl)piperazine Chemical compound [O-][N+](=O)C1=CC=CC(N2CCNCC2)=C1 LHHZRIYUOZPKSG-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CWORZSMRYNSMCN-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-6-(4-hydroxyphenyl)-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)N(CCOC1=CC=C(C=C1)NC=1N=CC2=C(N=1)N(C(C(=C2)C1=CC=C(C=C1)O)=O)C)CC CWORZSMRYNSMCN-UHFFFAOYSA-N 0.000 description 1
- RXINECZBKGCLEK-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethoxy]anilino]-6-(4-methoxyphenyl)-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C)N(CCOC1=CC=C(C=C1)NC=1N=CC2=C(N=1)N(C(C(=C2)C1=CC=C(C=C1)OC)=O)C)CC RXINECZBKGCLEK-UHFFFAOYSA-N 0.000 description 1
- ZJAVZNSTYFVSAG-UHFFFAOYSA-N 2-methylsulfanyl-6-phenyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound OC1=NC2=NC(SC)=NC=C2C=C1C1=CC=CC=C1 ZJAVZNSTYFVSAG-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MBNPJRQKQLLRIS-UHFFFAOYSA-N 3-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=CC(N)=C1 MBNPJRQKQLLRIS-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FSVYGMJRBWRMFH-UHFFFAOYSA-N 4-[2-(3-methylsulfonylanilino)quinazolin-6-yl]phenol Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)NC1=NC2=CC=C(C=C2C=N1)C1=CC=C(C=C1)O FSVYGMJRBWRMFH-UHFFFAOYSA-N 0.000 description 1
- WJDFQVQZUNCBGA-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1Cl)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C WJDFQVQZUNCBGA-UHFFFAOYSA-N 0.000 description 1
- VBZODFGFKXFBLY-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C VBZODFGFKXFBLY-UHFFFAOYSA-N 0.000 description 1
- PJXOTIYEIKVEGR-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)-8-methyl-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)C PJXOTIYEIKVEGR-UHFFFAOYSA-N 0.000 description 1
- DHLDFZDYTZKHEN-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC(=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C DHLDFZDYTZKHEN-UHFFFAOYSA-N 0.000 description 1
- JNKUZYYVHRNNPG-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-(2-methylpropyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)SC)N(C1=O)CC(C)C JNKUZYYVHRNNPG-UHFFFAOYSA-N 0.000 description 1
- BFHYOBKLKHMXFZ-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-(2-methylpropyl)-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)S(=O)(=O)C)N(C1=O)CC(C)C BFHYOBKLKHMXFZ-UHFFFAOYSA-N 0.000 description 1
- JTWDQFJHOKLOHG-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-8-methyl-2-(4-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C(=CC=C1)Cl)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=C2)S(=O)(=O)C)N(C1=O)C JTWDQFJHOKLOHG-UHFFFAOYSA-N 0.000 description 1
- CNHAKFYAPGFFRH-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C CNHAKFYAPGFFRH-UHFFFAOYSA-N 0.000 description 1
- CJNSVBCBWCPNMO-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-(pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC2=NC=CC=C2)N(C1=O)C CJNSVBCBWCPNMO-UHFFFAOYSA-N 0.000 description 1
- JXODUKPTDVRVRW-UHFFFAOYSA-N 6-(2-chlorophenyl)-8-methyl-2-(pyridin-3-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=C(C=CC=C1)C1=CC2=C(N=C(N=C2)NC=2C=NC=CC=2)N(C1=O)C JXODUKPTDVRVRW-UHFFFAOYSA-N 0.000 description 1
- HMHLUVLAKOYBNP-UHFFFAOYSA-N 6-(2-chlorophenyl)-N-(3-methylsulfonylphenyl)quinazolin-2-amine Chemical compound ClC1=C(C=CC=C1)C=1C=C2C=NC(=NC2=CC=1)NC1=CC(=CC=C1)S(=O)(=O)C HMHLUVLAKOYBNP-UHFFFAOYSA-N 0.000 description 1
- QDPCSLVQTXXDET-UHFFFAOYSA-N 6-(2-chlorophenyl)-N-[4-[2-(diethylamino)ethoxy]phenyl]quinazolin-2-amine Chemical compound ClC1=C(C=CC=C1)C=1C=C2C=NC(=NC2=CC=1)NC1=CC=C(C=C1)OCCN(CC)CC QDPCSLVQTXXDET-UHFFFAOYSA-N 0.000 description 1
- XIXAMNAQPOFORK-UHFFFAOYSA-N 6-(4-chlorophenyl)-8-methyl-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidin-7-one Chemical compound ClC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)NC2=CC(=CC=C2)S(=O)(=O)C)N(C1=O)C XIXAMNAQPOFORK-UHFFFAOYSA-N 0.000 description 1
- LRADTRCBCZVNHT-UHFFFAOYSA-N 6-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound [Si](C)(C)(C(C)(C)C)OC1=CC=C(C=C1)C1=CC2=C(N=C(N=C2)SC)N(C1=O)C LRADTRCBCZVNHT-UHFFFAOYSA-N 0.000 description 1
- KWZMLARYZJWIGD-UHFFFAOYSA-N 8-benzyl-6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C(C1=CC=CC=C1)N1C(C(=CC2=C1N=C(N=C2)NC1=CC=C(C=C1)OCCN(CC)CC)C1=C(C=CC=C1Cl)Cl)=O KWZMLARYZJWIGD-UHFFFAOYSA-N 0.000 description 1
- MOBSPJDIUFOWRW-UHFFFAOYSA-N 8-benzyl-6-(2,6-dichlorophenyl)-2-methylsulfanylpyrido[2,3-d]pyrimidin-7-one Chemical compound CSc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(Cc3ccccc3)c2n1 MOBSPJDIUFOWRW-UHFFFAOYSA-N 0.000 description 1
- MCUZSPMYZFXONZ-UHFFFAOYSA-N 8-benzyl-6-(2,6-dichlorophenyl)-2-methylsulfonylpyrido[2,3-d]pyrimidin-7-one Chemical compound C(C1=CC=CC=C1)N1C(C(=CC2=C1N=C(N=C2)S(=O)(=O)C)C1=C(C=CC=C1Cl)Cl)=O MCUZSPMYZFXONZ-UHFFFAOYSA-N 0.000 description 1
- ZEAGCABTPLPQOS-UHFFFAOYSA-N 8-ethyl-2-methylsulfanyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(SC)=NC=C2C=C1C1=CC=CC=C1 ZEAGCABTPLPQOS-UHFFFAOYSA-N 0.000 description 1
- VZRSUDPBMFMEEH-UHFFFAOYSA-N 8-ethyl-2-methylsulfonyl-6-phenylpyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1N(CC)C2=NC(S(C)(=O)=O)=NC=C2C=C1C1=CC=CC=C1 VZRSUDPBMFMEEH-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010056328 Hepatic ischaemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- CRZQGDNQQAALAY-UHFFFAOYSA-N Methyl benzeneacetate Chemical compound COC(=O)CC1=CC=CC=C1 CRZQGDNQQAALAY-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- JUDOSMOOLQAAQD-UHFFFAOYSA-N N-(3-methylsulfonylphenyl)-6-pyridin-2-ylquinazolin-2-amine Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)NC1=NC2=CC=C(C=C2C=N1)C1=NC=CC=C1 JUDOSMOOLQAAQD-UHFFFAOYSA-N 0.000 description 1
- USZMUEBWKFFRMB-UHFFFAOYSA-N N-(3-methylsulfonylphenyl)-6-pyridin-3-ylquinazolin-2-amine Chemical compound CS(=O)(=O)C=1C=C(C=CC=1)NC1=NC2=CC=C(C=C2C=N1)C=1C=NC=CC=1 USZMUEBWKFFRMB-UHFFFAOYSA-N 0.000 description 1
- 108700011067 Necrosome Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 101710092490 Protein kinase 3 Proteins 0.000 description 1
- 101150025038 RIPK3 gene Proteins 0.000 description 1
- 102000013070 Receptor-Interacting Protein Serine-Threonine Kinase 2 Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NMMPMZWIIQCZBA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylethanamine Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NMMPMZWIIQCZBA-UHFFFAOYSA-M 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- AAUBVINEXCCXOK-UHFFFAOYSA-N ethyl 4,6-dichloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C=C1Cl AAUBVINEXCCXOK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 102000054953 human ACVR1 Human genes 0.000 description 1
- 102000050354 human NOD2 Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ZLZZAXUKBHFTHA-UHFFFAOYSA-N n,n-diethyl-2-(4-nitrophenoxy)ethanamine Chemical compound CCN(CC)CCOC1=CC=C([N+]([O-])=O)C=C1 ZLZZAXUKBHFTHA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical group N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000003567 signal transduction assay Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Abstract
Description
本開示は、概して、受容体相互作用キナーゼ2(RIPK2)阻害活性および/またはアクチビン様キナーゼ2(ALK2)および/または受容体相互作用キナーゼ3(RIPK3)の阻害活性を示す化合物に関する。
本開示はタンパク質キナーゼ阻害剤およびそれらの使用に関する。
であってもよく、ここでXはFまたはMeであり、ここでMeはメチルである。R2はMe、Et、Et-O-Me、またはイソブチルであってもよい。R3は
であってもよく、ここでEtはエチルである。
式中、R2はEt(UH15-4)、Et-O-Me(UH15-6)、またはイソブチル(UH15-10)であり、式中、XはF(UH15-18)またはMe(UH15-20)である。
という置換基であってもよく、ここでMeはメチルであり、Etはエチルである。AおよびDは独立してNまたはCHであってもよい。EはN、CH、またはC-Rであってもよく、Rは上に規定したとおりである。BおよびCは独立してN、CH、またはC-Clであってもよい。R1はHであってもよいし、またはR1は環の任意の1つの利用可能な位置においてC-Cl、C-F、C-OCH3、C-C(CH3)3、もしくはC-OHであってもよい。X-YはC=Cであってもよいし、またはそれらは
であってもよく、ここでR2はHであるか、メチル、エチルまたはイソブチルを非限定的に含むアルキルであるか、2-ヒドロキシエチルを非限定的に含むアルキルヒドロキシルであるか、2-メトキシエチルを非限定的に含むアルキルアルコキシルであるか、またはベンジルもしくはフェネチルを非限定的に含むアルキルアリールである。
であってもよく、ここでR2はHであるか、メチル、エチルまたはイソブチルを非限定的に含むアルキルであるか、2-ヒドロキシエチルを非限定的に含むアルキルヒドロキシルであるか、2-メトキシエチルを非限定的に含むアルキルアルコキシルであるか、またはベンジルもしくはフェネチルを非限定的に含むアルキルアリールである。RはH、
であってもよく、ここでMeはメチルであり、Etはエチルである。R1はメチル、エチル、またはプロピルを非限定的に含む任意のアルキル基であってもよいし、またはR1はナフチル、チエニル、インドイルなどを非限定的に含む任意のアリール基であってもよい。R3はHであってもよいし、またはR3は環の任意の1つの利用可能な位置においてC-Cl、C-F、C-OCH3、C-C(CH3)3、もしくはC-OHであってもよい。
図4は、概してUH15アナログまたはUH15と呼ばれる、タンパク質キナーゼ活性の阻害剤として本明細書において開示される例示的な好ましい化合物の概略的な合成スキーム全体を示す。特に、以下の考察において、化合物は、例えば、UH15-1またはUH15_1の形式で言及されることがある。これらの化合物は異なる構造を有する。例えば、UH15-15はUH15_15とは異なる化合物である。
純度99.6%(tR23.51分).MP182~184℃.
活性:
下の表1は、選択したUH15アナログの活性を示す。組換えRIPK3の阻害、RIPK3を発現するLPS/IDN処理マウスRAW264.7マクロファージおよびTNF/IDN処理ヒトHela細胞におけるネクロトーシスの阻害、生細胞における阻害剤によるRIPK3結合(NanoBRETアッセイ)、ならびにRIPK3依存アポトーシスの誘導(すなわち、オン・ターゲット毒性)について、IC50/LD50値を決定した。アッセイはADPGlo(キナーゼアッセイ)、CellTiter-Glo(生存率)、およびNanoBRET(標的結合)アッセイを用いて実施した。示されたGSK'872値は2014年のMandalらによるものである。
阻害(%)=(1-(試験シグナル/最大シグナル))*100
GraphPad Prismソフトウェアにおける非線形回帰を用い、用量範囲の阻害剤濃度に基づいて、特定された濃度での阻害率を決定するかまたはIC50値を算出する。CellTiter-Gloアッセイには、10μM IDN6556(MedKoo)と組み合わせた10ng/ml hTNFα(Peprotech、Hela-R3細胞)または大腸菌(E.coli)LPS(Sigma、RAW264.7細胞)の存在下または非存在下で細胞を96ウェルプレート中で6~24時間処理してネクロトーシスを誘導する。薬物との培養後、15μLのCellTiter-Glo試薬をウェルに加え10分間培養する。発光シグナルは適切な発光プレートリーダーを用いて決定される(典型的な積分時間0.3秒)。生存率を算出するためには、以下:
生存率(%)=(1-(試験シグナル/未処理ウェルでの最大生存率))*100
図31は、選択したUH15化合物およびGSK'872がRAW264.7マクロファージにおいてRIPK3およびMLKLのリン酸化を遮断することを示す。ネクロトーシスはLPS(10ng/ml)と汎カスパーゼ阻害剤IDN6556(20μM)との組み合わせによって誘導された。LPSは、TNFと同様に、カスパーゼ阻害剤の存在下でRIPK3(およびネクロトーシス)を活性化できるTLR4リガンドであることに留意されたい。星印はpMLKLのイムノブロットにおいて時折見られる非特異的なバンドを表す。試料は、RIPK3、ホスホ-Thr231/Ser232-RIPK3、MLKLおよびホスホ-Ser345-MLKL抗体(Abcam)を用いたSDS-PAGEゲル電気泳動およびウエスタンブロッティングに供される。
表2は、選択したUH15アナログの刺激依存性(TNFあり、10ng/ml)および非依存性(TNFなし)のRIPK3依存性毒性を示す。細胞死をCellTiter-Gloアッセイによって評価した。毒性は、RIPK3を欠損させたHela細胞、およびRIPK3がレンチウイルスにより再発現された細胞(Hela-RIPK3細胞)において比較した。
組換えRIPK2タンパク質(反応あたり20ng)を40mM Tris(pH7.5);20mM MgCl2;0.1mg/mL BSA;50μM DTTからなる反応緩衝液で希釈する。希釈したタンパク質を低容量白色384ウェルプレートに加える(2μL/ウェル)。阻害剤を反応緩衝液(最終25%DMSO)で希釈し、各ウェルに1μL加え、5分間室温で培養する。反応は反応緩衝液への2μLの100μM ATPおよび1mg/mL RSリピートペプチド(SignalChem)の添加により開始される。プレートをプラスチックのカバーガラスで密封し、室温で2時間培養する。5μLのADP-Glo試薬(Promega)の添加により反応を停止させ、ADP生成反応を40分間室温で実施する。10μLのキナーゼ検出試薬(Promega)を添加して30分間室温により発光シグナルを生成させる。発光シグナルは適切な発光プレートリーダーを用いて決定される(典型的な積分時間0.3~1秒)。阻害率を算出するために、平均バックグラウンドシグナルを試験ウェルおよび最大シグナルウェルから減算する。
阻害(%)=(1-(試験シグナル/最大シグナル))*100
GraphPad Prismソフトウェアにおける非線形回帰を用い、用量範囲の阻害剤濃度に基づいて、特定された濃度での阻害率を決定するかまたはIC50値を算出する。
酵素阻害活性は、様々な濃度(10nM~100μM)の試験化合物の存在下で、ヒトALK2をタンパク質基質カゼイン(1mg/mL)およびγ-33ATP(10μM)と培養することによる標準的なキナーゼ酵素アッセイで評価した。30分後、33P-カゼインの量を決定した。阻害剤濃度対%活性の図を作製し、この図からIC50値を決定した。
ヒトNOD2およびNFkB-SAEPレポーター(Invivogen)を発現するHEK-Blue細胞を、10%FBSおよび1%抗生物質-抗真菌混合物を加えた100μLのDMEM培地中、96ウェル透明プレートに1ウェルあたり7.5×103個播種する。細胞は37℃の5%CO2組織培養インキュベーター内で48時間付着させる。実験当日の朝、ウェル内の培地を100μLのHEK-Blue検出培地(Invivogen)と交換する。DMSO(1ウェルあたり0.5μL)で希釈した阻害剤で細胞を15分間37℃の5%CO2組織培養インキュベーター内で処理する。その後、1ng/ウェルのL18-MDP(Invivogen)の添加により細胞を刺激する。細胞を37℃の5%CO2組織培養インキュベーター内で8時間培養し、培地中のSEAPに対応する吸光度をWallac3Vプレートリーダー(Perkin Elmer)で決定する。
阻害(%)=(1-((試料のシグナル-非刺激およびDMSO処理細胞)/(L18-MDP刺激およびDMSO処理細胞-非刺激およびDMSO処理細胞)))*100
GraphPad Prismソフトウェアにおける非線形回帰を用いて用量範囲の阻害剤濃度に基づいてIC50値を算出する。
調製した化合物は、上に記載の方法を用いて、RIPK2およびALK2酵素活性ならびにNOD2細胞シグナル伝達を阻害するそれらの能力について評価した。化合物によるRIPK2酵素およびNOD2細胞シグナル伝達の阻害について、特定された濃度での阻害率またはIC50値を下の表3に示す。化合物によるALK2酵素活性の阻害のIC50値も表3に示す。
Claims (13)
- 治療有効量の請求項1記載の化合物と、薬学的に許容される賦形剤、アジュバント、担体、緩衝剤、安定剤、またはそれらの混合物とを含む薬学的組成物。
- 請求項2記載の薬学的組成物を投与する工程
を含む、タンパク質キナーゼが関連する疾患または状態を治療する方法。 - 請求項2記載の薬学的組成物を投与する工程
を含む、受容体相互作用キナーゼ2(RIPK2)、アクチビン様キナーゼ2(ALK2)、または受容体相互作用キナーゼ3(RIPK3)の活性が関与する疾患または状態を治療する方法。 - 請求項2記載の薬学的組成物を投与する工程
を含む、受容体相互作用キナーゼ3(RIPK3)の活性が関与する炎症性または変性性の疾患または状態を治療する方法。 - 治療有効量の請求項6記載の化合物と、薬学的に許容される賦形剤、アジュバント、担体、緩衝剤、安定剤、またはそれらの混合物とを含む薬学的組成物。
- 請求項7記載の薬学的組成物を投与する工程
を含む、タンパク質キナーゼが関連する疾患または状態を治療する方法。 - 請求項7記載の薬学的組成物を投与する工程
を含む、受容体相互作用キナーゼ2(RIPK2)、アクチビン様キナーゼ2(ALK2)、または受容体相互作用キナーゼ3(RIPK3)の活性が関与する疾患または状態を治療する方法。 - 請求項7記載の薬学的組成物を投与する工程
を含む、受容体相互作用キナーゼ3(RIPK3)の活性が関与する炎症性または変性性の疾患または状態を治療する方法。 - 受容体相互作用キナーゼ3(RIPK3)阻害活性が関与する炎症性または変性性の疾患または状態を治療する方法であって、以下の工程を含む、方法:
以下の構造:
[式中、
1つの利用可能な環上位置において、RはHであるか、またはRは
であり、ここでMeはメチルであり、Etはエチルであり、
AおよびDは独立してNまたはCHであり、
EはN、CH、またはC-Rであり、
BおよびCは独立してN、CH、またはC-Clであり、
1つの利用可能な環上位置において、R1はHであるか、またはR1はC-Cl、C-F、C-OCH3、C-C(CH3)3、もしくはC-OHであり、かつ
X-YはC=Cまたは
であり、ここでR2はH、アルキル、アルキルヒドロキシル、アルキルアルコキシル、またはアルキルアリールである]
を有する治療有効量の化合物と、薬学的に許容される賦形剤、アジュバント、担体、緩衝剤、安定剤、またはそれらの混合物とを含む薬学的組成物を投与する工程。 - RIPK3活性が関与する炎症性または変性性の疾患または状態がA型インフルエンザウイルス(IAV)である、請求項11記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962848719P | 2019-05-16 | 2019-05-16 | |
US201962848648P | 2019-05-16 | 2019-05-16 | |
US62/848,719 | 2019-05-16 | ||
US62/848,648 | 2019-05-16 | ||
PCT/US2020/032784 WO2020232190A1 (en) | 2019-05-16 | 2020-05-14 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022533182A true JP2022533182A (ja) | 2022-07-21 |
JPWO2020232190A5 JPWO2020232190A5 (ja) | 2023-05-02 |
Family
ID=70919255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021568650A Pending JP2022533182A (ja) | 2019-05-16 | 2020-05-14 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220194937A1 (ja) |
EP (1) | EP3968991A1 (ja) |
JP (1) | JP2022533182A (ja) |
AU (1) | AU2020275304A1 (ja) |
CA (1) | CA3137869A1 (ja) |
WO (1) | WO2020232190A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018213219A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
CN113072471B (zh) * | 2021-03-02 | 2022-09-16 | 四川美大康华康药业有限公司 | 一种利非司特中间体及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
ATE286053T1 (de) * | 1997-08-20 | 2005-01-15 | Warner Lambert Co | Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung |
CZ20022521A3 (cs) * | 2000-01-27 | 2003-02-12 | Warner-Lambert Company | Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění |
WO2014031571A1 (en) * | 2012-08-21 | 2014-02-27 | Icahn School Of Medicine At Mount Sinai | Treatment of viral infections |
WO2015179436A1 (en) * | 2014-05-19 | 2015-11-26 | Sanford-Burnham Medical Research Institute | Inflammation therapy using mekk3 inhibitors or blocking peptides |
WO2018213219A1 (en) | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
-
2020
- 2020-05-14 WO PCT/US2020/032784 patent/WO2020232190A1/en active Application Filing
- 2020-05-14 US US17/595,406 patent/US20220194937A1/en active Pending
- 2020-05-14 CA CA3137869A patent/CA3137869A1/en active Pending
- 2020-05-14 AU AU2020275304A patent/AU2020275304A1/en active Pending
- 2020-05-14 EP EP20729566.8A patent/EP3968991A1/en active Pending
- 2020-05-14 JP JP2021568650A patent/JP2022533182A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020232190A1 (en) | 2020-11-19 |
EP3968991A1 (en) | 2022-03-23 |
AU2020275304A1 (en) | 2021-12-16 |
US20220194937A1 (en) | 2022-06-23 |
CA3137869A1 (en) | 2020-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6517928B2 (ja) | キナーゼ阻害剤として有用なインドールカルボキシアミド | |
KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
TWI433677B (zh) | 雜環化合物及其用途 | |
US9387204B2 (en) | Fused bicyclic imidazoles | |
JP6845939B2 (ja) | イソキノリンおよびナフチドリン化合物 | |
JP6533875B2 (ja) | Pde1阻害剤 | |
WO2019037678A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
US20080076924A1 (en) | Piperazines as P2X7 antagonists | |
TW201524959A (zh) | Kras g12c之抑制劑 | |
KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
US20160193206A1 (en) | Bet-protein-inhibiting dihydropyridopyrazinones | |
EA024984B1 (ru) | Производные 6-циклоалкил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве ингибиторов pde9a | |
JP2009532370A (ja) | インダゾール化合物 | |
WO2021143701A1 (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
JP6855636B2 (ja) | イミダゾリジン化合物 | |
US20240025916A1 (en) | Kras g12c inhibitors | |
AU2004283093A1 (en) | Compounds and compositions as protein kinase inhibitors | |
JP2022533182A (ja) | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 | |
US20170121322A1 (en) | Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups | |
TW201712011A (zh) | 作為bet家族溴結構域抑制劑之新穎吡啶吡酮 | |
WO2015193228A1 (de) | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe | |
US10550125B2 (en) | Prodrugs of imidazotriazine compounds as CK2 inhibitors | |
CN111205281B (zh) | 杂环化合物及其用途 | |
JP2024514844A (ja) | Myt1阻害剤を含む併用治療 | |
JP6834057B2 (ja) | 糖尿病の治療のためのpde1阻害剤としての[1,2,4]トリアゾロ誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230424 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230424 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240328 |